EMBioSys is excited to announce that Sachin Jhawar, MD has joined our Advisory Board! Dr. Jhawar specializes in Radiation Oncology with a focus on breast cancer, skin cancer and head & neck cancer at The James Comprehensive Cancer Center in Columbus Ohio. We look forward to Dr. Jhawar’s contribution towards our mission to dramatically improve cancer patient outcomes using our novel iEF Therapy.

We are pleased to announce that our Co-Founder and CEO, Chris Barron, will present EMBioSys’ iEF Therapy at the LSI USA Emerging Medtech Summit on March 19, 2025. This presentation highlights our mission to bring new hope to patients facing triple-negative breast cancer.

Co-Founder and CSO, Dr. Vish Subramaniam, will present at the American Association for Cancer Research on April 28, 2025. His poster highlights iEF Therapy research, which demonstrates promise in reducing tumor growth, preventing metastasis, and enhancing immune response for treatment of triple-negative breast cancer.

We proudly acknowledge our research partners at The Ohio State University for their work on iEF Therapy. Their presentations earned recognition at the Great Lakes Breast Cancer Research Symposium and GRASP Cancer, underscoring the importance of collaboration in advancing treatments for breast cancer patients worldwide.

Our President and Chief Scientific Officer, Dr. Vish Subramaniam, will speak at the National Cancer Institute’s Cancer Bioelectricity Conference on September 12, 2024. He will present on innovative bioelectric approaches, including EMBioSys’ iEF Therapy, aimed at improving treatment for metastatic solid tumors and supporting future breakthroughs in cancer care.

We are excited to welcome Tracey Wielinski, a Regulatory, Clinical, and Quality executive with 30 years of experience, to our Advisory Board. Tracey’s expertise in medical devices and pharmaceuticals will provide valuable guidance as EMBioSys advances iEF Therapy development and moves forward toward future clinical trials.

Rick Clemon has joined the EMBioSys Advisory Board. With over 30 years of financial leadership across life sciences and medical devices, Rick’s experience will be instrumental as we prepare for clinical trials. His dedication will help strengthen our mission to improve cancer treatment outcomes.

EMBioSys is honored to welcome Dr. Silvia Formenti, Chair of Radiation Oncology at Weill Cornell Medicine. A leader in translational cancer research, Dr. Formenti brings expertise in clinical trial design for metastatic breast cancer, lung cancer, and melanoma, supporting our mission to transform cancer patient outcomes.

We are thrilled to announce that EMBioSys has received an NIH/NCI SBIR Phase 1 Award to develop a wearable iEF Therapy device for metastatic triple-negative breast cancer. This award recognizes our technology’s potential and supports collaboration with Ohio State University on advancing cancer treatment innovation.

EMBioSys proudly welcomes Dr. Joe Camardo as a Medical Advisor. With 30 years of experience in oncology, inflammation, and vaccines, Dr. Camardo brings deep expertise in drug development. His guidance will accelerate the path of iEF Therapy to market, supporting improved treatment options for patients.

Jennifer Herron has joined EMBioSys as an Independent Board Director and Strategic Advisor. With strong leadership and a passion for advancing cancer therapies, Jennifer will provide critical guidance as EMBioSys moves toward clinical trials and continues building innovative solutions for cancer patients worldwide.